TCM
ALXN

Tekla Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tekla Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-64,453
Closed -$11.8M – 204
2021
Q2 		$11.8M Sell
64,453
-46,240
-42% -$7.94M 0.38% 68
2021
Q1 		$16.9M Sell
110,693
-391,249
-78% -$60.5M 0.58% 46
2020
Q4 		$78.4M Buy
501,942
+235,151
+88% +$30.2M 2.76% 6
2020
Q3 		$30.5M Sell
266,791
-117,918
-31% -$12.7M 1.14% 21
2020
Q2 		$43.2M Sell
384,709
-28,617
-7% -$3.04M 1.64% 16
2020
Q1 		$37.1M Sell
413,326
-22,488
-5% -$2.21M 1.68% 13
2019
Q4 		$47.1M Sell
435,814
-18,073
-4% -$1.93M 1.78% 13
2019
Q3 		$44.5M Buy
453,887
+53,873
+13% +$6.07M 1.94% 11
2019
Q2 		$52.4M Buy
400,014
+24,309
+6% +$3.13M 2.14% 11
2019
Q1 		$50.8M Sell
375,705
-120,583
-24% -$15M 2.06% 12
2018
Q4 		$48.3M Buy
496,288
+57,872
+13% +$6.84M 2.07% 12
2018
Q3 		$60.9M Hold
438,416
– – 2.21% 9
2018
Q2 		$54.4M Sell
438,416
-60,559
-12% -$7.08M 2.07% 12
2018
Q1 		$55.6M Sell
498,975
-160,643
-24% -$19.2M 2.16% 12
2017
Q4 		$78.9M Sell
659,618
-91,287
-12% -$11.1M 3.04% 7
2017
Q3 		$105M Hold
750,905
– – 3.77% 6
2017
Q2 		$91.4M Sell
750,905
-45,000
-6% -$5.24M 3.38% 9
2017
Q1 		$96.5M Hold
795,905
– – 3.74% 6
2016
Q4 		$97.4M Buy
795,905
+31,900
+4% +$3.9M 4.15% 4
2016
Q3 		$93.6M Buy
764,005
+82,200
+12% +$10.6M 3.6% 5
2016
Q2 		$79.6M Buy
681,805
+45,000
+7% +$6.38M 3.25% 6
2016
Q1 		$88.7M Hold
636,805
– – 3.77% 5
2015
Q4 		$121M Hold
636,805
– – 4.41% 6
2015
Q3 		$99.6M Buy
636,805
+52,500
+9% +$9.58M 3.58% 5
2015
Q2 		$106M Buy
584,305
+82,000
+16% +$14.2M 3.82% 6
2015
Q1 		$87M Buy
502,305
+25,200
+5% +$4.56M 3.45% 5
2014
Q4 		$88.3M Buy
477,105
+25,200
+6% +$4.67M 4.13% 4
2014
Q3 		$74.9M Buy
451,905
+116,006
+35% +$19.1M 3.51% 4
2014
Q2 		$52.5M Hold
335,899
– – 4.82% 6
2014
Q1 		$51.1M Sell
335,899
-35,430
-10% -$5.63M 5.11% 6
2013
Q4 		$49.4M Hold
371,329
– – 5.19% 5
2013
Q3 		$43.1M Hold
371,329
– – 4.8% 6
2013
Q2 		$34.3M Buy
+371,329
New +$35.8M 4.66% 6

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tekla Capital Management's ALXN Position: Q3 2021 in Review

Tekla Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 64,453 shares — an estimated $11.8M sold.

Tekla Capital Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $121M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Tekla Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 64,453 Alexion Pharmaceuticals shares in Q3 2021, an estimated $11.8M.
  • Tekla Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Tekla Capital Management's Alexion Pharmaceuticals position peaked at $121M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.